Oral COVID-19 Vaccine
Prevention of COVID-19
Pre-clinicalLegacy (Oravax)
Key Facts
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is focused on transforming the treatment of chronic diseases by developing oral versions of injectable therapies. Its core technology, the Protein Oral Delivery (POD™) platform, is designed to protect drug molecules as they pass through the gastrointestinal tract, enabling systemic absorption. The company's most advanced program is an oral insulin candidate, which has demonstrated safety and efficacy in multiple clinical trials and represents a significant market opportunity. Oramed is publicly traded and continues to explore applications of its platform beyond diabetes.
View full company profileTherapeutic Areas
Other Prevention of COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| Recombinant COVID-19 Vaccine (ZF2001) | Zhifei Biological Products | Approved |
| Novel Coronavirus mRNA Vaccine | Zhifei Biological Products | Clinical |
| COVID-19 Inactivated Vaccine (BBIBP-CorV) | Tiantan Bio | Approved |
| Recombinant COVID-19 Vaccine | Tiantan Bio | Phase 3 |
| MVA-BN (Multi-Variant) | Bavarian Nordic | Phase 2 |
| DMAb-1 | Inovio Pharmaceuticals | Phase 1 |
| DMAb-2 | Inovio Pharmaceuticals | Phase 1 |
| SARS-CoV-2 Vaccine | Auro Vaccines | Poised for Clinical |